Oral steroids ineffective in the treatment of preschool virus-induced wheezing

Jan 21, 2009

A new study from Barts and The London School of Medicine and Dentistry has found that a common treatment for wheezing in preschool children is no more effective than a placebo.

The findings, reported in the January edition of The New England Journal of Medicine, call into question national guidelines for the treatment of viral-induced wheezing.

Attacks of wheezing caused by viral infections in the upper respiratory tract are common in preschool children between the ages of ten months and six years. Preschool children who visit hospital with such symptoms are commonly treated with a short course of prednisolone - a steroid which is used to reduce inflammation in the airway and which is very effective in treating attacks of allergic asthma in older children and adults.

It has recently been recognised that wheeze in most preschool children is only triggered by viral colds, and is therefore a different condition from 'allergic asthma'. There is conflicting evidence whether a short course of oral prednisone is effective in this age group.

Professor Jonathan Grigg, a paediatrician at Barts and The London's, Institute of Cell and Molecular Science, along with colleagues from Leicester and Nottingham Universities, studied a group of 700 children between the ages of 10 and 60 months, who presented to hospital with an attack of wheezing associated with a viral infection. Half were treated with oral prednisolone, half with a placebo, and symptoms monitored by health care professionals.

The team found no significant difference in the length of time the children spent in hospital between the placebo group and the prednisolone group. These findings were consistent with a previous study conducted by the team, where the oral steroid was administered by parents in the home.

Professor Grigg explains: "The result of this large trial suggests that oral prednisolone should not be routinely given to preschool children presenting to the hospital with virus-induced wheezing."

Source: Queen Mary, University of London

Explore further: Mirabegron for overactive bladder: Added benefit not proven

add to favorites email to friend print save as pdf

Related Stories

A novel gene found for childhood-onset asthma

Dec 23, 2009

Pediatric researchers have identified a novel gene involved in childhood asthma, in one of the largest gene studies to date of the common respiratory disease. Because the gene, called DENND1B, affects cells and signaling ...

Warning over codeine use after tonsillectomy

Aug 19, 2009

A report out of The University of Western Ontario, published in the New England Journal of Medicine, warns the use of codeine to treat pain following a tonsillectomy could prove fatal for some children. Dr. Gideon Koren, ...

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

12 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments : 0